Free Trial

Solid Biosciences (NASDAQ:SLDB) Given Market Outperform Rating at JMP Securities

Solid Biosciences logo with Medical background

JMP Securities reaffirmed their market outperform rating on shares of Solid Biosciences (NASDAQ:SLDB - Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $16.00 price target on shares of Solid Biosciences in a research report on Thursday, May 22nd. Chardan Capital cut their price objective on Solid Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a report on Monday, May 19th. Wedbush lowered their target price on Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, May 16th. Barclays lowered their price target on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Finally, Piper Sandler reduced their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Ten investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Solid Biosciences currently has a consensus rating of "Buy" and an average price target of $14.90.

View Our Latest Stock Analysis on Solid Biosciences

Solid Biosciences Stock Performance

Shares of SLDB stock traded up $0.29 on Friday, hitting $4.54. The company had a trading volume of 1,607,044 shares, compared to its average volume of 1,121,046. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $10.37. The stock's 50-day moving average is $3.12 and its two-hundred day moving average is $3.98. The firm has a market cap of $351.92 million, a P/E ratio of -1.49 and a beta of 2.32.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). Equities research analysts predict that Solid Biosciences will post -2.84 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Woodline Partners LP purchased a new stake in shares of Solid Biosciences in the 1st quarter valued at approximately $2,338,000. Goldman Sachs Group Inc. boosted its position in Solid Biosciences by 32.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company's stock valued at $667,000 after buying an additional 43,910 shares during the period. EcoR1 Capital LLC purchased a new stake in shares of Solid Biosciences during the 1st quarter worth $2,754,000. Bain Capital Life Sciences Investors LLC lifted its position in shares of Solid Biosciences by 96.1% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock worth $29,273,000 after purchasing an additional 3,877,087 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Solid Biosciences during the 1st quarter worth $418,000. Institutional investors and hedge funds own 81.46% of the company's stock.

About Solid Biosciences

(Get Free Report)

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

See Also

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Should You Invest $1,000 in Solid Biosciences Right Now?

Before you consider Solid Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.

While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines